Anxian Yuan China Holdings Limited (0922) AI Stock Analysis

• Market Cap: HK$370.97M
• Dividend Yield: 2.96%
• Average Volume (3M): 4.24M
• Price to Earnings (P/E): 7.3
• Beta (1Y): 0.20
• Revenue Growth: -16.88%
• EPS Growth: -11.54%
• Country: HK
• Employees: 226
• Sector: Consumer Cyclical
• Sector Strength: 64
• Industry: Personal Products & Services
• EPS (TTM): 0.01
• Shares Outstanding: 2,221,363,000
• 10 Day Avg. Volume: 5,031,234
• 30 Day Avg. Volume: 4,238,111
• PEG Ratio: -0.58
• Price to Book (P/B): 0.37
• Price to Sales (P/S): 1.46
• P/FCF Ratio: 5.10
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 64 Neutral
• Price Target: HK$0.00 ▼(-100.00% Downside)

The overall stock score of 64 reflects a stable financial performance with strong profit margins and a solid balance sheet, but challenges in revenue growth and profitability. The technical analysis indicates bearish momentum, which is a concern for short-term investors. However, the stock's low P/E ratio and attractive dividend yield suggest potential undervaluation, making it appealing for value investors.

Anxian Yuan China Holdings Limited Business Overview & Revenue Model

Company Description

Anxian Yuan China Holdings Limited (0922) is a Hong Kong-based investment holding company that primarily operates in the sectors of healthcare and consumer products. The company focuses on the development, manufacturing, and distribution of healthcare-related products, particularly in traditional Chinese medicine, as well as a range of consumer goods aimed at improving quality of life. Anxian Yuan aims to leverage the growing demand for natural and wellness products in both domestic and international markets.

How the Company Makes Money

Anxian Yuan generates revenue through multiple streams, primarily from the sale of its healthcare products and consumer goods. The company has established partnerships with various suppliers and distributors to enhance its market reach. Its business model includes direct sales to consumers, as well as wholesale distribution to retail outlets. Additionally, the company benefits from the increasing popularity of traditional Chinese medicine, which allows it to capitalize on the growing trend of holistic health solutions. Strategic collaborations and joint ventures with other companies in the healthcare sector also contribute to its revenue, enabling Anxian Yuan to expand its product offerings and market penetration.

Anxian Yuan China Holdings Limited Financial Statement Overview

Summary

Anxian Yuan China Holdings Limited shows a mixed financial performance. The balance sheet is strong with low leverage and strong equity, but income and cash flow statements reveal declining revenue, profitability, and cash generation. The company needs to improve operational efficiency and revenue growth to enhance financial health.

Income Statement

The income statement shows a declining trend in revenue, with a decrease from 2023 to 2024. The Gross Profit Margin remains healthy, but the Net Profit Margin has also decreased due to lower net income. EBIT and EBITDA margins have shrunk, indicating reduced operational efficiency. Overall, profitability has weakened, but gross margins are still strong.

Balance Sheet

The balance sheet reflects a strong equity position with a high equity ratio, supported by low total debt. The Debt-to-Equity ratio is favorable, reflecting low leverage. Return on Equity has decreased, indicating reduced profitability on shareholders' investments. Overall, the company maintains a stable financial structure with low financial risk.

Cash Flow

Cash flow analysis reveals a significant decline in operating cash flow, coupled with a drop in free cash flow. The Free Cash Flow to Net Income ratio remains positive, indicating efficient cash generation relative to income. However, the decline in free cash flow growth suggests potential challenges in sustaining cash generation. Overall, cash flow management remains adequate but shows a declining trend.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	250.25M	236.43M	284.43M	340.53M	310.95M	298.74M
Gross Profit	181.84M	172.98M	207.73M	251.41M	220.18M	212.94M
EBITDA	97.03M	98.85M	106.40M	165.78M	135.67M	139.97M
Net Income	49.19M	51.08M	57.82M	104.92M	73.13M	80.30M
Balance Sheet
Total Assets	1.30B	1.28B	1.28B	1.33B	1.34B	1.34B
Cash, Cash Equivalents and Short-Term Investments	323.90M	329.70M	339.43M	340.53M	209.87M	255.94M
Total Debt	33.55M	44.59M	17.74M	45.27M	49.45M	131.43M
Total Liabilities	326.38M	309.91M	296.46M	325.89M	335.74M	405.37M
Stockholders Equity	936.70M	937.65M	942.97M	970.33M	965.29M	897.19M
Cash Flow
Free Cash Flow	62.16M	67.51M	84.81M	184.43M	66.84M	104.58M
Operating Cash Flow	67.87M	72.45M	91.64M	186.51M	69.14M	109.02M
Investing Cash Flow	-45.65M	-129.85M	57.77M	-60.79M	-2.63M	-7.41M
Financing Cash Flow	-44.12M	-12.69M	-79.74M	-33.65M	-131.30M	63.93M

Anxian Yuan China Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.17
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0922, the sentiment is Positive. The current price of 0.17 is below the 20-day moving average (MA) of 0.17, above the 50-day MA of 0.17, and above the 200-day MA of 0.16, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 50.43 is Neutral, neither overbought nor oversold. The STOCH value of 47.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0922.

Anxian Yuan China Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0922	64 Neutral	HK$370.97M	7.26	5.43%	2.96%	-16.88%	-11.54%
6966	64 Neutral	HK$465.00M	43.46	4.32%	1.18%	-24.33%	-45.69%
Sector *	62 Neutral	C$4.63B	8.07	17.93%	3.89%	2.21%	-1.75%
1448	61 Neutral	HK$8.29B	20.38	6.48%	12.28%	-22.77%	-53.94%
8296	54 Neutral	HK$49.14M	―	-7.04%	―	0.98%	-4.81%

Anxian Yuan China Holdings Limited Corporate Events

Anxian Yuan China Holdings Announces 2025 AGM Agenda

Anxian Yuan China Holdings Limited has announced the notice for its upcoming annual general meeting scheduled for September 8, 2025. The meeting will address several key resolutions, including the adoption of financial statements, declaration of a final dividend, re-election of directors, and re-appointment of auditors. Additionally, the company seeks approval to empower its directors to allot and issue shares within specified limits, which could impact the company’s capital structure and shareholder value.

Anxian Yuan China Holdings Limited Establishes Audit Committee Guidelines

Anxian Yuan China Holdings Limited has outlined the terms of reference for its Audit Committee. The committee will consist of at least three members, primarily independent non-executive directors, and will meet at least twice a year to oversee the company’s financial reporting and audit processes. This move is expected to enhance the company’s governance and accountability, potentially impacting its operations positively by ensuring rigorous financial oversight.

Anxian Yuan China Holdings Limited Updates Nomination Committee Terms

Anxian Yuan China Holdings Limited has outlined the terms of reference for its Nomination Committee, which was established in 2012. The committee is responsible for reviewing the board’s structure and composition, identifying suitable director candidates, and assessing the independence of non-executive directors. This move reflects the company’s commitment to maintaining robust corporate governance practices, potentially enhancing shareholder value and aligning the board’s capabilities with corporate strategy.

Anxian Yuan China Holdings Limited Defines Remuneration Committee Terms

Anxian Yuan China Holdings Limited has outlined the terms of reference for its Remuneration Committee, which was established in compliance with the Corporate Governance Code. The committee is responsible for recommending the company’s remuneration policy and structure, ensuring a formal and transparent procedure for developing remuneration policies, and reviewing management’s remuneration proposals. This move is expected to enhance the company’s governance practices, potentially impacting its operational transparency and stakeholder confidence.

Anxian Yuan China Holdings Limited Reports Annual Results for 2025

Anxian Yuan China Holdings Limited announced its annual results for the year ending March 31, 2025, reporting a decrease in revenue to HK$236.4 million from HK$284.4 million the previous year. Despite the decline in revenue, the company maintained profitability with a net profit of HK$52.3 million, although this was lower than the previous year’s HK$58.4 million, indicating a challenging year with reduced sales and increased finance costs impacting overall performance.

Anxian Yuan China Holdings Announces Final Dividend for FY2025

Anxian Yuan China Holdings Limited announced a final ordinary cash dividend of HKD 0.011 per share for the financial year ending March 31, 2025. The dividend, approved by shareholders on September 8, 2025, will be paid on October 3, 2025, with the record date set for September 12, 2025. This announcement reflects the company’s ongoing commitment to returning value to its shareholders and may influence investor sentiment and market positioning.

Anxian Yuan China Holdings Schedules Board Meeting for Financial Results and Dividend Decision

Anxian Yuan China Holdings Limited has announced that its board of directors will convene on June 20, 2025, to consider and approve the audited consolidated annual results for the year ending March 31, 2025. The meeting will also address the potential recommendation of a final dividend payment. This announcement is significant as it outlines the company’s financial performance evaluation and potential shareholder returns, which could impact investor sentiment and market positioning.